EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia

Zongru Li, Xiaoshuai Zhang, Yijing Zhao, Linping Lu, Yong Guo, Robert Peter Gale, Yazhen Qin, Qian Jiang iD

Cancer · 2025

DOI: 10.1002/cncr.35565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Zongru Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, C…. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myeloid, Chronic-Phase, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Nova Program of Science and Technology, Peking University People's Hospital Research and Development Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In people with chronic‐phase chronic myeloid leukemia (CML) receiving imatinib and achieving major molecular response (MMR), dose reduction may decrease adverse events but may be associated with a loss of molecular response. Whether digital droplet polymerase chain reaction (ddPCR) can identify persons in whom dose reduction might be unsuccessful is unknown.

Methods

Data from 716 consecutive subjects who achieved MMR after initial imatinib therapy (400 mg/day) were obtained. A total of 486 subjects remained on full‐dose imatinib, whereas 230 subjects had their dose reduced to 300 or 200 mg/day. The outcomes of these cohorts were compared via landmark and propensity score matching analyses.

Results

Imatinib dose reduction showed no significant effect on the subsequent achievement of deeper molecular responses (4‐ and 4.5‐log reductions in BCR::ABL1 transcripts; MR 4 and MR 4.5 ), maintenance of MMR, or attainment of therapy‐free remission when compared with subjects without dose reduction. In subjects achieving MR 4 , however, the probability of maintaining MR 4 ( p = .002) was lower in the reduced‐dose group. In multivariable analyses, failure to achieve MR 4.5 as determined by ddPCR at the time of dose reduction was significantly associated with briefer MMR failure‐free survival (FFS; hazard ratio [HR], 10.3; 95% confidence interval [CI], 1.3–82.9; p = .03) and MR 4 FFS (HR, 6.8; 95% CI, 2.6–18.0; p < .001).

Conclusions

Imatinib dose reduction after achieving MMR does not adversely affect response deepening or MMR maintenance in chronic‐phase CML but compromises MR 4 maintenance. The results of ddPCR may identify people who benefit from imatinib dose reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateLeukemia, Myeloid, Chronic-PhaseAntineoplastic AgentsHumansMaleFemaleMiddle AgedAdultAgedFusion Proteins, bcr-ablTreatment OutcomeDose-Response Relationship, DrugProtein Kinase Inhibitors

Stichwörter der Autor:innen

chronic myeloid leukemiadeep molecular responsedigital droplet polymerase chain reactiondose reductionimatinib

Substanzen

Imatinib MesylateAntineoplastic AgentsFusion Proteins, bcr-ablProtein Kinase Inhibitors

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
  • School of Biomedical Engineering, Tsinghua University, Beijing, China.
  • TargetingOne Corporation, Beijing, China.
  • Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, UK.
  • Peking University People's Hospital, Qingdao, China.

ORCID-Profile: Qian Jiang

Förderung

  • National Natural Science Foundation of China
  • Beijing Nova Program of Science and Technology
  • Peking University People's Hospital Research and Development Funds
  • Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation

Zitieren

APA

Li, Z., Zhang, X., Zhao, Y., Lu, L., Guo, Y., Gale, R. P., Qin, Y., & Jiang, Q. (2025). Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia. Cancer. https://doi.org/10.1002/cncr.35565

Vancouver

Li Z, Zhang X, Zhao Y, Lu L, Guo Y, Gale RP, et al. Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia. Cancer. 2025. doi:10.1002/cncr.35565

BibTeX
@article{Li2025,
  author = {Li, Zongru and Zhang, Xiaoshuai and Zhao, Yijing and Lu, Linping and Guo, Yong and Gale, Robert Peter and Qin, Yazhen and Jiang, Qian},
  title = {Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35565}
}
Kostenlos starten →